These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 7755361

  • 41. Are cognitive changes the first symptoms of Huntington's disease? A study of gene carriers.
    Hahn-Barma V, Deweer B, Dürr A, Dodé C, Feingold J, Pillon B, Agid Y, Brice A, Dubois B.
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):172-7. PubMed ID: 9489526
    [Abstract] [Full Text] [Related]

  • 42. Monozygotic twins suffering from Huntington's disease show different cognitive and behavioural symptoms.
    Gómez-Esteban JC, Lezcano E, Zarranz JJ, Velasco F, Garamendi I, Pérez T, Tijero B.
    Eur Neurol; 2007 Feb; 57(1):26-30. PubMed ID: 17108691
    [Abstract] [Full Text] [Related]

  • 43. Cognitive changes in asymptomatic carriers of the Huntington disease mutation gene.
    Verny C, Allain P, Prudean A, Malinge MC, Gohier B, Scherer C, Bonneau D, Dubas F, Le Gall D.
    Eur J Neurol; 2007 Dec; 14(12):1344-50. PubMed ID: 17941857
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Attention, inhibition, and proximity to clinical onset in preclinical mutation carriers for Huntington's disease.
    Farrow M, Churchyard A, Chua P, Bradshaw JL, Chiu E, Georgiou-Karistianis N.
    J Clin Exp Neuropsychol; 2007 Apr; 29(3):235-46. PubMed ID: 17454345
    [Abstract] [Full Text] [Related]

  • 46. Longitudinal cognitive and motor changes among presymptomatic Huntington disease gene carriers.
    Kirkwood SC, Siemers E, Stout JC, Hodes ME, Conneally PM, Christian JC, Foroud T.
    Arch Neurol; 1999 May; 56(5):563-8. PubMed ID: 10328251
    [Abstract] [Full Text] [Related]

  • 47. Attempt at preclinical identification of Huntington's disease using the WAIS.
    Strauss ME, Brandt J.
    J Clin Exp Neuropsychol; 1986 Jun; 8(3):210-8. PubMed ID: 2941451
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Clinical manifestations of intermediate allele carriers in Huntington disease.
    Cubo E, Ramos-Arroyo MA, Martinez-Horta S, Martínez-Descalls A, Calvo S, Gil-Polo C, European HD Network.
    Neurology; 2016 Aug 09; 87(6):571-8. PubMed ID: 27402890
    [Abstract] [Full Text] [Related]

  • 51. Relationship between evoked potential and neuropsychological findings in persons "at risk" for Huntington's disease.
    Josiassen RC, Curry LM, Mancall EL, Shagass C, Roemer RA.
    J Clin Exp Neuropsychol; 1986 Jan 09; 8(1):21-36. PubMed ID: 2935556
    [Abstract] [Full Text] [Related]

  • 52. Psychiatric symptoms and CAG repeats in neurologically asymptomatic Huntington's disease gene carriers.
    Berrios GE, Wagle AC, Marková IS, Wagle SA, Ho LW, Rubinsztein DC, Whittaker J, Ffrench-Constant C, Kershaw A, Rosser A, Bak T, Hodges JR.
    Psychiatry Res; 2001 Jul 24; 102(3):217-25. PubMed ID: 11440772
    [Abstract] [Full Text] [Related]

  • 53. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year.
    Lemiere J, Decruyenaere M, Evers-Kiebooms G, Vandenbussche E, Dom R.
    Acta Neurol Scand; 2002 Sep 24; 106(3):131-41. PubMed ID: 12174172
    [Abstract] [Full Text] [Related]

  • 54. Cognitive Dysfunction Contributes to Mobility Impairments in Huntington's Disease.
    Kloos AD, Kegelmeyer DA, Fritz NE, Daley AM, Young GS, Kostyk SK.
    J Huntingtons Dis; 2017 Sep 24; 6(4):363-370. PubMed ID: 29254103
    [Abstract] [Full Text] [Related]

  • 55. Cognitive Performance and Apathy Predict Unemployment in Huntington's Disease Mutation Carriers.
    Jacobs M, Hart EP, Roos RAC.
    J Neuropsychiatry Clin Neurosci; 2018 Sep 24; 30(3):188-193. PubMed ID: 29325477
    [Abstract] [Full Text] [Related]

  • 56. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression.
    Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A.
    PLoS One; 2007 Jul 25; 2(7):e647. PubMed ID: 17653274
    [Abstract] [Full Text] [Related]

  • 57. Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset.
    Jason GW, Suchowersky O, Pajurkova EM, Graham L, Klimek ML, Garber AT, Poirier-Heine D.
    Arch Neurol; 1997 Sep 25; 54(9):1081-8. PubMed ID: 9311351
    [Abstract] [Full Text] [Related]

  • 58. Identification of symbol digit modality test score extremes in Huntington's disease.
    Braisch U, Muche R, Rothenbacher D, Landwehrmeyer GB, Long JD, Orth M, REGISTRY Investigators of the European Huntington's Disease Network and COHORT Investigators of the Huntington Study Group.
    Am J Med Genet B Neuropsychiatr Genet; 2019 Apr 25; 180(3):232-245. PubMed ID: 30788902
    [Abstract] [Full Text] [Related]

  • 59. Preparing for preventive clinical trials: the Predict-HD study.
    Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E, Predict-HD Investigators of the Huntington Study Group.
    Arch Neurol; 2006 Jun 25; 63(6):883-90. PubMed ID: 16769871
    [Abstract] [Full Text] [Related]

  • 60. Confirmation of subtle motor changes among presymptomatic carriers of the Huntington disease gene.
    Kirkwood SC, Siemers E, Bond C, Conneally PM, Christian JC, Foroud T.
    Arch Neurol; 2000 Jul 25; 57(7):1040-4. PubMed ID: 10891987
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.